$9m placement to advance US biodefence opportunity
Filed with ASX · · 3 pages · English
• Island well positioned for significant upside, with Animal Rule approval unlocking eligibility for US Government procurement and a Priority Review Voucher, recently valued at ~US$200m MELBOURNE Australia, 4 February 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to advise it has secured firm commitments to raise $9m th
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- FDA confirms Galidesivir approval pathway
- Quarterly Appendix 4C and Activities Report
- US Patent Granted for Galidesivir in filoviridae viruses
- Ongoing engagement with the US FDA
- Agreement with Texas Biomed for Galidesivir Program
Later from Island Pharmaceuticals
- Response to ASX Query Letter
- Appendix 4D & Half-Year Financial Statements
- Trading Halt
- US Government collaboration for Galidesivir development
- Antiviral pipeline expansion through strategic collaboration
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals